Positive results from human clinical study concluded on Feno-Chaga® Organic

Eevia Health Plc (" Eevia" or" The Company") has concluded a human clinical study of the effects of Eevia's branded ingredient Feno-Chaga® Organic on Upper-Respiratory Tract Infections (URTIs) and Psychological Mood State with positive and promising results.

Forty (40) healthy long-distance (marathon) runners participated in a research study investigating the effects of a one-month dietary supplementation of Feno-Chaga® Organic on their physical and psychological well-being. The hypothesis was that Feno-Chaga® Organic might improve immune system vigilance in the test group, compared to the control group. Twenty males and females received Feno-Chaga® Organic, while another same size group received a placebo.

To stress and suppress the immune system of the volunteers, participants trained for and completed a strenuous endurance running event (half-marathon to marathon distance) to induce physical and mental stress. This endurance event created a "susceptibility window," whereby a higher risk for upper-respiratory-tract infections (URTIs) is more likely to be observed. Feno-Chaga® Organic may be a natural "immune-modulator," which may balance overall immune system activity and either stimulate a suppressed immune system (up to optimal) or suppress an overactivated immune system (down to optimal). An adequately primed immune system "pays attention" to factors it should fight, such as viruses, bacteria, cancer cells, etc. On the other hand, it ignores factors that should be considered non-harmful, such as pollen, mucus membranes, joint cartilage, etc.

In the study, we observed that the Feno-Chaga® group experienced the following positive benefits of supplementation compared to the placebo group:

  • There was a 51% reduction in upper-respiratory tract symptoms (total number of reported symptoms such as cough, sore throat, sniffles, stuffiness, etc.)
  • A 10% improvement in overall well-being (global mood state)
  • A 61% increase in microbiome species S. Thermophilus, which is known to be involved in immune-system regulation
  • A 30% reduction in cortisol (primary stress hormone)

The study concluded that Feno-Chaga® Organic significantly decreased URTI incidence and improved psychological mood state compared to Placebo. An abstract of the study can be found at Eevia Health webpages www.eeviahealth.com. The results will be presented at a scientific conference. Eevia Health will use the results in the market positioning of its branded product Feno-Chaga® Organic as an effective ingredient in immunomodulating dietary supplements. Scientifically documenting the efficacy of Eevia's plant extracts is essential as a crucial factor in growing customer interest and sales.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                       Kim Nurmi-Aro, CFO, Eevia Health Plc

Email: [email protected]                      [email protected]

Telephone: +358 400 22 5967                             +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a fast-growing Finnish manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. Eevia's branded ingredients, such as Feno-Myrtillus® Organic (high concentrate bilberry extracts with 36% anthocyanins) and Fenoprolic® 70 Organic (pine bark extracts with 70% oligomeric proanthocyanidins), are organically certified. 

Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

 Subscribe   Documents & Links

Eevia Health Plc receives a 230 KSEK/21 KEUR starting sales order for a new Lingonberry product to a new customer

Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.


Eevia Health Plc has secured a credit line of SEK 8 million for working capital purposes to finance continued growth

Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.


Communique from the Annual General Meeting in Eevia Health Plc

The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:


Eevia Health Plc receives a 2,3 MSEK/0,23 MEUR sales order for organic bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.


Notice of the Annual General Meeting of Shareholders 2022

The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.


Eevia Health Plc publishes Financial Statements for 2021

Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.



Eevia Health Plc successfully participates at Vitafoods trade show in Geneva

Eevia Health Plc, ("Eevia" or "The Company"), is taking part in the trade show "Vitafoods" in Geneva this week (10-12 May 2022).


Eevia Health Plc receives a 3,3 MSEK/0,33 MEUR sales order for bilberry extract

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.


Eevia Health appoints a Shareholders' Nomination Committee

Eevia Health Plc, ("Eevia" or "The Company") has appointed a Shareholders' Nomination Committee


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted